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Summary
Very–long-chain acyl-CoA dehydrogenase (VLCAD)
catalyzes the initial rate-limiting step in mitochondrial
fatty acid b-oxidation. VLCAD deficiency is clinically
heterogenous, with three major phenotypes: a severe
childhood form, with early onset, high mortality, and
high incidence of cardiomyopathy; a milder childhood
form, with later onset, usually with hypoketotic hypo-
glycemia as the main presenting feature, low mortality,
and rare cardiomyopathy; and an adult form, with iso-
lated skeletal muscle involvement, rhabdomyolysis, and
myoglobinuria, usually triggered by exercise or fasting.
To examine whether these different phenotypes are due
to differences in the VLCAD genotype, we investigated
58 different mutations in 55 unrelated patients repre-
senting all known clinical phenotypes and correlated the
mutation type with the clinical phenotype. Our results
show a clear relationship between the nature of the mu-
tation and the severity of disease. Patients with the severe
childhood phenotype have mutations that result in no
residual enzyme activity, whereas patients with the
milder childhood and adult phenotypes have mutations
that may result in residual enzyme activity. This clear
genotype-phenotype relationship is in sharp contrast to
what has been observed in medium-chain acyl-CoA de-
hydrogenase deficiency, in which no correlation between
genotype and phenotype can be established.
Received October 12, 1998; accepted for publication December 9,
1998; electronically published February 5, 1999.
Address for correspondence and reprints: Dr. Brage Storstein An-
dresen, Research Unit for Molecular Medicine, Skejby Sygehus, DK
8200 A˚rhus N, Denmark. E-mail: brage@biobase.dk
 1999 by The American Society of Human Genetics. All rights reserved.
0002-9297/99/6402-0018$02.00
Introduction
Oxidation of fatty acids in the mitochondria provides
the main source of energy in heart and skeletal muscle.
Moreover, during periods of fasting, ketone bodies pro-
duced by mitochondrial fatty acid oxidation in the liver
become the major source of the body’s energy needs.
Not surprisingly, inherited defects in any of the individ-
ual steps of mitochondrial b-oxidation can be expected
to result in significant clinical disease. So far, as many
as 16 inherited defects affecting the b-oxidation of
straight-chain fatty acids have been described (Roe and
Coates 1995).
Very–long-chain acyl-CoA dehydrogenase (VLCAD)
is one of four acyl-CoA dehydrogenases, with different
chain-length specificity, that catalyze the initial rate-lim-
iting step in mitochondrial b-oxidation of fatty acids
(Beinert 1963; Aoyama et al. 1995b). Patients with de-
fects in short-chain acyl-CoA dehydrogenase (SCAD)
and medium-chain acyl-CoA dehydrogenase (MCAD)
have been known of for many years (Kølvraa et al. 1982;
Amendt et al. 1987). The first patients with VLCAD
deficiency were identified as early as 1985 (Hale et al.
1985), but, because the VLCAD enzyme had not yet
been identified, these patients were believed to have long-
chain acyl-CoA dehydrogenase (LCAD) deficiency. In
1993, two groups of investigators characterized for the
first time the enzyme defect in patients with VLCAD
deficiency (Aoyama et al. 1993; Bertrand et al. 1993),
and more recently, it has been demonstrated that patients
previously believed to have LCAD deficiency have
VLCAD deficiency instead (Aoyama et al. 1995b; Lar-
gillie`re et al. 1995). On the basis of clinical data from
seven VLCAD patients, Aoyama and coworkers (1995b)
suggested that VLCAD deficiency may give rise to more-
severe disease than the other b-oxidation defects. Ac-
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cording to these investigators, VLCAD deficiency is
characterized by disease onset in the first few months of
life, frequently in the neonatal period; a high mortality
rate (75%); and cardiomyopathy in the majority of pa-
tients. In contrast to this, the patients studied by our
group (Bertrand et al. 1993; Andresen et al. 1996a) gen-
erally had a milder phenotype. Recently, Vianey-Saban
and coworkers (1998) reported the results of a study of
27 families with established VLCAD deficiency. They
reported that the childhood patients could be grouped
into two major clinical phenotypes: a severe childhood
form, similar to that in the patients described byAoyama
and coworkers (1995b), and a milder phenotype, with
delayed disease onset, a lower mortality rate, absence of
cardiomyopathy, and hypoketotic hypoglycemia as the
main presenting feature. In addition, it is becoming ev-
ident that a third phenotypic form of the disease exists,
namely, a muscular form that presents after childhood
exclusively as muscle disease leading to rhabdomyolysis
and myoglobinuria, which is often exercise induced and
progressive (Ogilvie et al. 1994; Minetti et al. 1998;
Smelt et al. 1998).
The human VLCAD cDNA (Aoyama et al. 1995a;
Andresen et al. 1996a) and genomic sequence (Strauss
et al. 1995) were identified only a few years ago, and
consequently only a small number of patients have been
studied at the molecular level. Despite this, 17 different
pathogenic mutations have been identified (Aoyama et
al. 1995a; Strauss et al. 1995; Andresen et al. 1996a,
1996b; Souri et al. 1996, 1998a, 1998b; Smelt et al.
1998), indicating that the mutational spectrum in
VLCAD deficiency is diverse. In view of the variable
clinical phenotypes in this disease, it is tempting to spec-
ulate that they could be explained by differentmutations
in the VLCAD gene that result in different levels of re-
sidual enzyme activity. In other inherited diseases—for
example, phenylketonuria—it has been demonstrated
that such a correlation between mutation type and dis-
ease phenotype can be made (Desviat et al. 1997; Ka-
yaalp et al. 1997). The relationship between genotype
and phenotype has also been examined in two defects
of fatty acid oxidation. In MCAD deficiency there is no
clear-cut genotype-phenotype relationship (Andresen et
al. 1997). However, in carnitine palmitoyltransferase
(CPT II) deficiency, which, like VLCAD deficiency, af-
fects the metabolism of long-chain fatty acids, some cor-
relation between genotype and phenotype has been re-
ported (Taroni et al. 1993; Verderio et al. 1995; Bon-
nefont et al. 1996; McGarry and Brown 1997).
In the present study we have investigated and char-
acterized the mutations responsible for the VLCAD de-
ficiency in 55 unrelated patients representing all the
known clinical phenotypes of the disease and have cor-
related the mutation types with the clinical phenotypes.
Material and Methods
Patients
We studied 55 families in which the index case had
experienced clinical symptoms of VLCAD deficiency
(Ogilvie et al. 1994; Roe and Coates 1995; Smelt et al.
1998). In 44 of the families included in the study, the
enzyme defect was demonstrated in cultured skin fibro-
blasts from the index patient by measurement of de-
hydrogenation of palmitoyl-CoA, with electron transfer
flavoprotein (ETF) used as the electron-acceptor (Frer-
man and Goodman 1985). The enzyme activity of ma-
trix and membrane fractions with palmitoyl-CoA as sub-
strate was assayed in triplicate as described elsewhere
(Bertrand et al. 1993; Vianey-Saban et al. 1998). In 14
patients who were not tested by the ETF assay, the en-
zyme defect was inferred from measurement of the b-
oxidation activity in intact cultured fibroblasts with
[9,10-3H]myristate, [9,10-3H]palmitate, and [9,10-3H]o-
leate used as substrates, as described elsewhere (Man-
ning et al. 1990; Olpin et al. 1997). In all patients
investigated, the enzyme defect was also indicated by
one or more of the following: an abnormal acylcarnitine
profile in plasma measured by tandem mass spectrom-
etry (Millington et al. 1992), dicarboxylic aciduria with-
out glycine conjugates measured by gas chromatogra-
phy/mass spectrometry (GC/MS), analysis of urine,
identification and quantitation of intermediates of un-
saturated fatty acid metabolism in plasma by GC/MS
analysis (Onkenhout et al. 1995; Costa et al. 1997), and
oxidation of 14C-labeled palmitic acid in intact fibro-
blasts (Vianey-Saban et al. 1998). To define the disease
phenotypes, we collected data on the clinical and bio-
chemical findings in all investigated patients apart from
one patient for whom the data were insufficient for cat-
egorization. The clinical and biochemical characteristics
of the patients are summarized in table 1. The case his-
tories of 12 of the patients included in this study have
been published previously (Bertrand et al. 1993; Ogilvie
et al. 1994; Onkenhout et al. 1995; Andresen et al.
1996a; Brown-Harrison et al. 1996; Gillett et al. 1996;
Merinero et al. 1996; Nada et al. 1996; Costa et al.
1998; Smelt et al. 1998). Moreover, patients from 14 of
the families included in the present study were studied
clinically and biochemically by Vianey-Saban et al.
(1998).
Preparation of DNA
Genomic DNA was isolated from cultured fibroblasts
or blood samples according to standard methods (Gus-
tafson et al. 1987). DNA was liberated from blood spots
and cultured cells as described elsewhere (Gregersen et
al. 1991b; Andresen et al. 1992).
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Table 1
Clinical Classification of Patients and Correlation of Genotype to Phenotype
PERCENT WITH PHENOTYPE PERCENT WITH GENOTYPE
VARIABLE
TOTAL
(n  54)
Severe
Childhood
(n  25 [46%])
Mild
Childhood
(n  21 [39%])
Adult
Onset
(n  8 [15%])
Two Null
Mutationsa
(n  15 [28%])
Two Missense
Mutations/Single–
Amino Acid Deletion
(n  18 [33%])
Age at onset:
!3 d 48 76 33 0 80 44
1–11 mo 22 24 29 0 13 17
1–4 years 15 0 38 0 7 11
113 years 15 0 0 100 0 28
Index patient dead 37 80 0 0 73 17
Dead sibs older than index patient 33 56 19 0 67 33
Families with dead children 50 92 19 0 93 39
11 episode in first 2 years of life
or died in first episode
57 100 29 0 87 44
Cardiomyopathy 52 92 19 13 73 24
Hepatomegaly 61 80 62 0 80 29
Rhabdomyolysis/myoglobinuria 20 0 14 100 0 33
Hypotonia 50 52 62 13 40 29
Hypoketotic hypoglycemia with-
out cardiomyopathy as main
presenting symptom
30 0 76 0 7 24
NOTE.—Data are percentages indicating the proportion of patients who have the feature in question.
a The R573W and delK258 mutations were categorized as null mutations on the basis of expression data from Souri et al. (1996).
PCR Amplification and Direct Sequencing of the Entire
VLCAD Protein-Coding Region
PCR amplifications of all exons, including part of the
flanking intron sequences of the human VLCAD gene,
were performed with both M13 forward- (21) and
M13 reverse-tagged intron-located primers under stan-
dard conditions in an automated thermal cycler (thermal
cycler 480, Perkin-Elmer). Primer sequences are avail-
able on request (from B.S.A.). The PCR products were
subjected to direct bidirectional cycle sequencing by
means of DNA dye primer sequencing kits (Prism,
TaqFS, and BigDye, Perkin-Elmer) in an ABI Catalyst
800 Molecular Biology LabStation (Applied Biosys-
tems). Sequence reactions were performed on semiau-
tomated ABI 373A and ABI 377 sequencers (Applied
Biosystems).
Extraction of Total RNA, Northern Blot Analysis, cDNA
Synthesis, PCR Amplification of VLCAD cDNA, and
Cloning of Amplified VLCAD cDNA
Extraction of total RNA from patient and control fi-
broblasts was performed by means of an RNAzol kit
(WAK-Chemie). Northern blot analysis of 15 mg of total
RNA from patients and controls was performed, as de-
scribed elsewhere, with the VLCAD probe (Andresen et
al. 1996a)—a probe specific for intron 10 of the VLCAD
gene—and a b-actin probe (Clontech). Four nylon filters
containing similar amounts of poly-(A) mRNA from
different human tissues (MTN-blot I, Clontech) were
also used for northern hybridization. To ensure that the
observed results are representative, we obtained filters
from different batches.
First-strand cDNA synthesis and PCR amplification
of VLCAD cDNAs were performed as described else-
where (Andresen et al. 1996a). PCR products were an-
alyzed by agarose gel electrophoresis. Fragments were
cut out of the gel, purified (Qiagen gel extraction kit),
and either subjected to direct sequencing or cloned into
a pCRII vector (InVitrogen) or a PCRScript vector (Stra-
tagene).
Expression of Wild-Type and Mutant VLCAD in COS-7
Cells
A fragment comprising the entire coding region of
human VLCAD cDNA, from a position 42 bp upstream
of the ATG start codon to cDNA position 2046, was
amplified under standard conditions by means of Turbo
Pfu polymerase (Stratagene) from liver cDNA, with a
sense primer introducing an EcoRI site and an antisense
primer introducing an XbaI site. This fragment was di-
gested with EcoRI and XbaI and cloned into the poly-
linker of the expression vector pCDNA 3.1 (In-
Vitrogen). Resulting clones were sequenced, and one
clone (HVLCp9), which harbored a sequence error in
the 5′ end of the VLCAD cDNA insert, was chosen for
further cloning. A fragment spanning the interval from
the NheI site in the polylinker to the HindIII site in the
HVLCAD cDNA sequence of HVLCp9 was replaced
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with a fragment spanning the interval from the SpeI site
in the polylinker to the internal HindIII from a PCR
error-free 5′ RACE clone characterized previously (An-
dresen et al. 1996a). The resulting plasmid (named
“pHVLC-WT”) was sequenced, and no PCR errors were
identified. To introduce the V243A and T220M muta-
tions into pHVLC-WT, HVLCAD cDNA from patients
harboring these mutations was amplified with Turbo Pfu
and digested with KpnI and HindIII, and the resulting
fragment was purified and cloned back into the plasmid
pHVLC-WT, replacing the corresponding fragment of
the wild-type sequence. To confirm that only the mu-
tations, and no PCR-derived errors, were present in the
exchanged fragments, we sequenced the constructed
plasmids, named “pHVLC-V243A” and “pHVLC-
T220M.”
Transfection of COS-7 cells was performed accord-
ing to a standard calcium phosphate coprecipitation
method, and expression of VLCAD protein was as-
sayed 36 h posttransfection from cells transfectedwith
pHVLC-WT, pHVLC-V243A, pHVLC-T220M, and
pCDNA 3.1, respectively. The conditions for growth
and transfection of cells have been described elsewhere
(Jensen et al. 1992).
Aliquots containing ∼25 mg of total protein from the
cleared supernatant of lysates from the transfectedCOS-
7 cells were tested by western blot analysis, as described
below. Measurement of VLCAD activity was by ferri-
cenium assay that used palmitoyl-CoA as substrate (Leh-
man et al. 1990; Scholte et al. 1992). All transfections
were performed at least twice, and enzyme activity was
measured in duplicate.
Western Blot Analysis
Frozen cell pellets from transfected COS-7 cells and
cultured fibroblasts from patients and controls were
lysed in 100 ml of lysis buffer (50 mM Tris-HCL at 7.7
pH, 5 mM EDTA at 7.4 pH, 1% Triton X-100, 250
mM sucrose, 1 mM DTT, 10 mg/ml leupeptin, 10 mg/ml
aprotinin, and 1 mM phenylmethylsulfonyl fluoride).
After 1 ml of Benzonase was added, the lysates were
incubated at 37C for 1 h before centrifugation at 10,000
g for 3 min. The cleared lysates were transferred to new
vials, and the protein concentrationwas determinedwith
a modified Bradford assay kit (BioRad). SDS-polyacryl-
amide gel electrophoresis and western blot analysis with
our VLCAD antibody (Andresen et al. 1996a) and an
antibody directed against ETF as a control were per-
formed as described elsewhere (Andresen et al. 1996a).
LCAD Mutation–Specific Assay
We designed a PCR/restriction enzyme cleavage–based
mutation-specific assay for the 997ArC mutation in
LCAD cDNA (Yamaguchi et al. 1993). The assay is
based on the principle of PCR-based introduction of
diagnostic and control restriction enzyme sites for the
restriction enzymeMboI. Primer sequences are available
on request (from B.S.A.). The assay was carried out as
described, elsewhere, for similar assays (Gregersen et al.
1991b; Andresen et al. 1992, 1997), with genomic DNA
used as the template for the PCR.
Identification and Characterization of the 463-bp
Sequence Upstream from the ATG Translation-
Initiation Codon of the Human VLCAD Gene
Adaptor-ligated genomic DNAs from a Genome-
Walker kit (Human GenomeWalker kit, Clontech) were
amplified as recommended by the supplier with the
adaptor primers AP1 (first amplification) and AP2 (sec-
ond amplification) and the gene-specific primers44AS
(first amplification) and 55AS (second amplification)
(Human GenomeWalker kit, Clontech). Information
about primers is available on request (from B.S.A.). In
one of the libraries (EcoRV) we obtained a product of
∼700 bp. By direct sequencing of this product, we ob-
tained 463 bp of sequence upstream from the ATG start
codon. A fragment spanning the identified 463-bp se-
quence was amplified and sequenced from DNA from
VLCAD patients and Danish controls, under standard
conditions.
Results
Clinical Presentation
The clinical and biochemical findings in our patients
are summarized in table 1. The data show a broad clin-
ical spectrum of disease, with all the known phenotypes
being presented—two childhood forms and one adult
form (Vianey-Saban et al. 1998). As illustrated in the
table, the severe childhood form is characterized by early
onset of symptoms, usually in the neonatal period, and
a high mortality rate or recurrent disease episodes, with
low tolerance of fasting. Cardiomyopathy is frequently
observed in this group of patients. The milder childhood
form (table 1) is characterized by delayed onset of symp-
toms with low mortality and often occurrence of only
a single episode or a few mild episodes of metabolic
decompensation. Cardiomyopathy is rare, and the main
clinical feature at presentation is hypoketotic hypogly-
cemia. Hepatomegaly and hypotonia are frequently ob-
served in both childhood forms. The adult form of the
disease (table 1) is characterized by onset of disease after
childhood, isolated skeletal muscle involvement with re-
current episodes of muscle pain, rhabdomyolysis, and
myoglobinuria, usually triggered by exercise or fasting
(Ogilvie et al. 1994; Minetti et al. 1998; Smelt et al.
1998; Straussberg et al. 1997). The 55 patients mani-
fested the three phenotypes as follows: 25, severe child-
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hood; 21, milder childhood; and 8, adult onset. One
patient could not be categorized because of insufficient
clinical and biochemical data. Residual VLCAD enzyme
activities did not differ significantly in cultured fibro-
blasts from patients with the different clinical pheno-
types. This has been observed previously (Vianey-Saban
et al. 1998) and probably occurs because the assays are
undertaken for diagnostic purposes rather than for com-
parison of residual enzyme activities. The fact that our
patients are of many different ethnic origins (there are
patients from 19 different countries located in North
and South America, Australia, Europe, Asia, and Africa)
demonstrates that VLCAD deficiency is not primarily a
disease affecting white people, as is observed with
MCAD deficiency (Tanaka et al. 1997).
Sequence Analysis by Direct Sequencing of the Entire
VLCAD Protein-Coding Region
We analyzed 55 index patients by sequencing the en-
tire VLCAD protein-coding region, and available family
members from 21 of the families were tested for the
relevant mutations (36 different mutations) by sequence
analysis. In table 2, the mutations identified are listed
along with the number of patients harboring them. Our
results show that the mutational spectrum is very wide,
with 58 different mutations—only 18 of which are pre-
sent in 11 patient—identified in 110 mutant alleles from
55 unrelated patients. In 47 families we identified mu-
tations in both VLCAD alleles from the index patient,
but in 8 families we could identify the mutation in only
one of the two alleles. In five patients we identified three
mutations in their two VLCAD alleles (table 2). The
nature of the double mutant alleles could be established
when the patient was homozygous (the V243A/V277A
allele and the G3D/R429W allele) or when the mutant
alleles from the patient were cloned and sequenced
(V243A/V277A and delE341/L562I [Andresen et al.
1996a]). Interestingly, the V243A, R429W, and delE341
mutations were also observed without the V277A, G3D,
and L562I mutations, respectively, in other patients. The
V277A, G3D, and L562I mutations were not observed
without the simultaneous presence of the V243A,
R429W, and delE341 mutations. This could indicate
that the V243A, R429W, and delE341 mutations have
arisen more than once, or that the V277A, G3D, and
L562I mutations have occurred on alleles already har-
boring the other mutations.
There were 42 different single base pair substitutions,
14 of which were located in a CpG dinucleotide and
could have resulted from the mutational mechanism of
deamination of a 5′-methylated C residue (Coulondre et
al. 1978). There is evidence that the CpG dinucleotides
in the codon for arginine326 and arginine429 are mu-
tational hot spots, since CrT (R326C and R429W) and
GrA (R326H and R429Q) mutations of the CpG di-
nucleotide are present in both codons. Together with the
facts discussed above, this could indicate that the
R429Wmutation has arisen twice, once in an allele with
the G3D mutation and once in an allele without it. The
G3D mutation is probably not disease associated, since
mouse VLCAD (GenBank/European Molecular Biology
Laboratories [EMBL] accession number Z71189) has a
glutamate at this position, indicating that a negatively
charged residue, such as aspartate, is tolerated at this
position.
Thirty-one of the identified mutations changed an
amino acid (missense mutations), and three of the mu-
tations resulted in a single–amino acid deletion. All ex-
cept three (L462P, L562I, and R573W) of the missense
and single–amino acid deletion mutations were located
in the acyl-CoA dehydrogenase domain, which displays
a high similarity to the other acyl-CoA dehydrogenase
enzymes (Andresen et al. 1996a). However, only seven
of them were located in codons of amino acid residues
that are completely conserved.
Twelve of the identified mutations were small deletion/
insertions that altered the reading frame, resulting in
introduction of a premature-termination codon (PTC).
In addition, three mutations directly created a PTC, and
nine mutations affected VLCAD mRNA splicing by
changing splice consensus sequences or introducing new
3′ splice sites. All the splice mutations (except the
GgrCac and 2TrC mutations in intron 10) were ex-
amined by northern blot analysis of fibroblast total RNA
from patients and/or analysis of PCR-amplified cDNA
(see fig. 1 and below). They were all shown to affect
splicing severely, resulting in production of misspliced
VLCAD mRNAs that were present in severely decreased
amounts (table 2). All 15 of the PTC mutant VLCAD
mRNAs, as well as the misspliced VLCAD mRNAs (ex-
cept the 6GrA mutation in intron 18), encode a
VLCAD protein that would be missing essential parts
of the enzyme, such as the active site glutamate 422
(Souri et al. 1998a), if they were to be translated. Similar
to the splice mutations, all examined PTC mutations
were shown to have resulted in severely decreased
amounts of normal-sized VLCAD mRNA (see table 2
and below). Given this, we believe that all 15 PTC mu-
tations and the 9 splice mutations should result in no
residual VLCAD enzyme activity.
Northern Blot Analysis—Intron 10 Retention
We performed northern blot analysis of fibroblast to-
tal RNA from 46 of the patients and 4 controls with the
VLCAD probe (Andresen et al. 1996a). As shown in
figure 1A, two bands with varying intensities were de-
tected in the patients. The presence of a weak band that
migrated more slowly than the normal-sized VLCAD
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Figure 1 A, Northern blot analysis of fibroblast total RNA from three patients (1– 3) and poly(A) mRNA from different human tissues,
performed with a full-length VLCAD cDNA probe (I) and a VLCAD intron 10–specific probe (II). Patients 1 and 2 both have two PTCmutations,
and patient 3 has two missense mutations. H  heart tissue, B  brain, P  placenta, LU  lung, LI  liver, M  skeletal muscle, K  kidney,
and PA  pancreas). “Normal” indicates normal-sized VLCAD mRNA, and “INT 10” indicates the position of the VLCAD mRNA with
intron 10 retained. B,PCR of VLCAD cDNA from four patients and different human tissues, performed with a sense primer located in exon
7 and an antisense primer located in exon 12. Patients 1 and 4 both have two PTC mutations, and patients 2 and 3 both have two missense
mutations. S  size marker, and BL  blank amplification with no cDNA added. Other abbreviations are the same as in A. C, PCR of full-
length VLCAD cDNA from human liver, performed with primers located in exon 1 (sense) and exon 20 (antisense). Abbreviations are the same
as in A and B.
mRNA band has also been observed previously, and it
was suggested that it was caused by nonspecific hybrid-
ization of the very G/C-rich probe (Andresen et al.
1996a). This band is also visible in northern blots pro-
duced in other laboratories but has not been discussed
(Souri et al. 1996). We observed that in patients with
two mutations that result in the introduction of a PTC
in the VLCAD mRNA—either directly, because of small
insertions/deletions, or indirectly, as a result of mis-
splicing—the normal-sized VLCAD mRNA band was
absent, but the slower-migrating band was still present
(fig. 1A). Because we had, at the same time, observed
two bands of equal intensities (fig. 1C) when we am-
plified the entire coding region of VLCAD from human
liver cDNA, we began to suspect that the slower-mi-
grating band was not caused by nonspecific hybridiza-
tion but instead represented an alternative form of
VLCAD mRNA. Cloning and sequence analysis of the
two bands, amplified from human liver cDNA, showed
that they had identical sequences, except that the slower-
migrating band also contained the entire intron 10 se-
quence. We then used a probe that exclusively recognizes
intron 10 for hybridization of our patient northern blots
and four multiple-tissue northern blots. This showed
that the slower-migrating band indeed harbors intron 10
and that the normal-sized band was absent when the
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Figure 2 Expression of wild-type and mutant VLCAD in COS-
7 cells.Upper panel,Activity measurements are indicated as percentage
of wild-type VLCAD. Bars are mean values of duplicate measurements
from two separate transfection experiments. Thin lines indicate the
maximum and minimum value measured. Lower panel, Western blot
of COS-7 cells harboring expression vectors encoding wild-type (WT)
and V243A and T220M mutant VLCAD protein, respectively. The
control is COS-7 cells harboring the expression vector pcDNA3.1
with no VLCAD cDNA insert (vector).
blots were hybridized with the intron 10–specific probe.
Hybridization of the blots with probes specific for hu-
man MCAD and LCAD (Andresen et al. 1996a) pro-
duced only a single band of the expected size, indicating
that the blots did not harbor significant amounts of
unspliced nuclear mRNA.
We also investigated VLCAD cDNA from 41 of our
patients and from eight different tissue types from con-
trol individuals (human Multiple Tissue cDNA panel)
by PCR amplification that used four sets of primers lo-
cated in different exons flanking intron 10. In figure 1B,
the results obtained with one set of primers (sense primer
in exon 7 and antisense primer located in exon 12) used
in four patients and eight different human control tissues
are shown. Two major bands were observed, excised
from the gel, and shown by sequence analysis to rep-
resent either normal VLCAD cDNA sequence or normal
VLCAD cDNA sequence with intron 10 retained. The
third weak band that was observed was most probably
a heteroduplex band.
As illustrated in the figure, patients with two PTC/
splice mutations had very small amounts (nearly none)
of the band representing the normal VLCAD mRNA,
but the intron 10–containing band was still present and
more abundant. In patients with two missense muta-
tions, the band corresponding to normal VLCAD
mRNA was the most abundant, and much smaller
amounts of the intron 10–containing mRNA were ob-
served. This pattern is consistent with our results from
the northern blots and, together with our results from
sequence analysis of amplified cDNAs, shows that all of
the six PTC mutations and seven splice mutations that
could be examined in this way result in severely de-
creased amounts of normal-sized VLCAD mRNA (table
2).
Sequence analysis of intron 10 showed that it is 267
bp long and that an in-frame stop codon is present.
Translation of the intron 10–containing VLCADmRNA
would result in a protein of ∼41 kD. This protein would
be devoid of enzyme activity, since it lacks important
parts of the VLCAD enzyme, such as the active site glu-
tamate 422. The role of intron 10 retention is not clear
at present, but one could speculate that it represents
some sort of regulation, and it is interesting to note that
the tissue-specific distribution of the VLCAD mRNA
with intron 10 retention differs from that of the normal-
sized VLCAD mRNA, with the highest amounts ob-
served in liver and pancreas tissue.
Although the role of the VLCAD mRNA with intron
10 retained remains obscure, we do know that the intron
10–containing VLCAD mRNA encodes a nonfunctional
protein. Therefore, we conclude that patients in whom
we observe only the intron 10–containing VLCAD
mRNA cannot be expected to produce functional
VLCAD enzyme.
Expression of Wild-Type and Mutant VLCAD in COS-7
Cells
As an initial approach to test the molecular defect of
the missense mutations, we decided to analyze the two
most frequently observed missense mutations, V243A
(in nine unrelated families) and T220M (in five unrelated
families), by overexpression of mutant protein in COS-
7 cells. Measurements of the VLCAD activity in COS-
7 cells showed that cells transfected with the pHVLC-
WT plasmid, encoding wild-type VLCAD protein, had
an enzyme activity approximately six times higher than
the endogenous enzyme activity observed in cells trans-
fected with the pCDNA3.1 vector without VLCAD
cDNA inserted. Both cells transfected with the pHVLC-
V243A plasmid and those transfected with the pHVLC-
T220M plasmid had an enzyme activity above the en-
dogenous level. The V243A and T220M mutant
VLCADs had ∼20%–25% and ∼5% residual enzyme
activity, respectively. Western blot analysis (fig. 2)
showed that immunoreactive protein with a size corre-
sponding to that of mature VLCAD protein (66 kD) was
present both in cells expressing wild-type VLCAD and
in cells expressing the mutant proteins V243A and
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Figure 3 Western blot analysis of total fibroblast protein from
a normal control (N) and four VLCAD patients (lanes 1–4), performed
with anti-VLCAD and anti-ETF antibodies.
T220M. The amounts of immunoreactive protein ob-
served in cells harboring the expression vector without
VLCAD cDNA inserted (representing the endogenous
VLCAD protein) were much lower than the amounts
observed in cells transfected with expression vectors for
wild-type or mutant VLCAD. The amounts of immu-
noreactive protein observed in the transfected cells were
proportional to the corresponding enzyme activities (fig.
2), indicating that the mutant proteins have considerable
amounts of enzyme activity and that themolecular defect
mainly affects the amounts of mutant protein formed.
Western Blot Analysis of Patient Cells
Cultured fibroblasts harboring 43 differentmutations,
from 37 of the patients, were analyzed by western blot
analysis with our VLCAD antibody and an antibody
directed against ETF as a control. In figure 3, the results
from analysis of four patients and a control are shown.
In all analyzed patient tissues, the amounts of immu-
noreactive VLCAD protein were reduced, although to
different degrees, compared with normal controls (table
2). Therefore, we conclude that, in all examined patients,
the mutations led to drastically reduced amounts of im-
munoreactive protein.
Testing for 44 Different Mutations Located in Exons
8–15 in 100 Normal Alleles
Forty-four of the 58 different mutations identified in
the patients (located in 54 different alleles) are located
in exons 8–15 (table 2). These 44 different mutations
represent 82 of the 102 mutant alleles identified in the
patients. Thus, we could screen for 80% of all mutant
VLCAD alleles by sequencing six amplicons (exons 8,
9, 10, 11, 12-13, and 14-15). To investigate whether the
44 mutations are present in normal controls, we am-
plified these amplicons in tissue samples from 50 Danish
control individuals and sequenced them in one direction.
None of the 44 different mutations were observed in any
of the 100 alleles tested. This indicates that none of the
mutations are polymorphic in a white population such
as Danes.
LCAD Variants
We investigated the frequency of the 997A and 997C
LCAD variant alleles (Yamaguchi et al. 1993) in Danish
control individuals and in our patients, using a muta-
tion-specific assay. Our results (table 3) show that the
LCAD variant alleles are polymorphic in the Danish
population and that the frequencies of the two variant
alleles in our patients do not differ significantly from
those of the control population. Moreover, western blot
analysis, with an LCAD antibody, of fibroblasts from
patients with LCAD 997C/997C, 997A/997C, or 997A/
997A genotypes revealed no apparent difference in the
amounts of immunoreactive LCAD protein (results not
shown).
Sequence Analysis of the 463-bp Sequence Upstream
of the ATG Translation-Initiation Codon of the Human
VLCAD Gene in Patients and Controls
To search for mutations located in regulatory se-
quences, we identified and characterized 463 bp of nu-
cleotide sequence upstream from the ATG translation-
initiation codon of the human VLCAD gene. Using our
463-bp upstream sequence to search GenBank (using
BLASTn at the National Center for Biotechnology In-
formation), we identified an HTGS sequence (accession
number AC003688) from a chromosome 17–derived
clone that showed 97% identity in the entire 463-bp
overlap. The HTGS sequence showed similar high iden-
tity to the nucleotide sequence of the entire VLCAD gene
(accession number L46590). This indicates that our se-
quence indeed represents the 463-bp continuous se-
quence upstream of the VLCAD translation-initiation
codon. Computer analysis (PatSearch 1.1 and Mat-
Inspector 2.2, using Transfac 3.4 at the Transcription
Element Search System site) and manual analysis iden-
tified potential binding sites for several transcription fac-
tors, some of which have previously been identified in
the promoter region of the human MCAD gene (Zhang
et al. 1992). This indicates that the 463-bp upstream
sequence may have some regulatory function. This is
corroborated by our observation that the 463-bp se-
quence shows promoter activity when inserted in a lu-
ciferase reporter construct (B. S. Andresen, unpublished
data).
We then amplified and sequenced the 463-bp fragment
in tissue samples from 39 of our patients. The only dif-
ference detected was a deletion of a 15-bp perfect repeat
sequence corresponding to position64 to78 relative
to the ATG start codon (Andresen et al. 1996a). This
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Table 3
No. of Alleles with Each of the LCAD Variant Alleles
ALLELE
TOTAL
PATIENTSa
PHENOTYPEa
CONTROLSa
Mild
Childhood
Severe
Childhood
Adult
Onset
977A (K333) 68/108 (63) 25/42 (60) 32/48 (67) 9/16 (56) 86/126 (68)
977C (Q333) 40/108 (37) 17/42 (40) 16/48 (33) 7/16 (44) 40/126 (32)
a Values in parentheses are percentages.
15-bp deletion was identified in either homozygous or
heterozygous form in 23 patients in whom we had al-
ready identified mutations in the coding region of both
VLCAD alleles. Interestingly, five of six examined pa-
tients, in whom we had identified only one mutation
in the coding region of one of their VLCAD alleles,
were homozygous for the promoter sequence with the
normal sequence (GenBank/EMBL accession numbers
AJ012053 and X86556). Forty-two percent of patient
alleles had the 15-bp deletion and 58% had the normal
sequence. Investigation of 58 Danish control individuals
showed the 15-bp repeat variation to be polymorphic,
with an allele distribution of 43% with the 15-bp de-
letion and 57% with the normal sequence. Thus, the 15-
bp deletion does not seem to be pathogenic by itself but
may serve as an allelic marker. The 463-bp sequence has
been deposited in the GenBank/EMBL database (acces-
sion number AJ012053).
Discussion
It is apparent from the present study and previous
studies that VLCAD deficiency is a clinically heteroge-
neous disease that can be divided into three major dis-
ease phenotypes (Ogilvie et al. 1994; Roe and Coates
1995; Aoyama et al. 1995b;Andresen et al. 1996a; Smelt
et al. 1998; Vianey-Saban et al. 1998). The aim of this
study was to investigate whether these disease pheno-
types can be explained by differences in patient geno-
types.
Our results confirm that the mutational spectrum in
VLCAD deficiency is very wide. In the 55 patients in-
vestigated, we identified 58 different mutations, of which
45 have not been reported previously. This means that
a total of 62 mutations are now known in the VLCAD
gene. In marked contrast to MCAD deficiency and
LCHAD deficiency (Gregersen et al. 1991a, 1991b;Yok-
ota et al. 1991; Ijlst et al. 1994), there is no prevalent
pathogenic mutation. The pathogenic nature of the mu-
tations identified in our patients was supported by sev-
eral lines of evidence: The entire protein-coding region
was sequenced in all patients, ensuring that the identified
mutations were the only mutations present. All of the
44 different mutations that were investigated were ex-
cluded in 100 alleles from normal controls. Twenty-four
of the identified mutations were present in more than
one patient allele, and, in all 21 families investigated,
the identified mutations were located in separate alleles
and segregated with the disease. Furthermore, results
from northern blot analysis, analysis of VLCAD cDNA,
western blot analysis, and overexpression of some of the
mutant proteins in eukaryotic cells indicate that the iden-
tified mutations are indeed pathogenic.
In addition to our investigation of the protein-coding
part of the VLCAD gene, we identified and characterized
463 bp of sequence upstream of the VLCAD translation-
initiation codon both in patients and in normal controls.
We did not identify any variations in this region, except
for a 15-bp deletion that was found to be polymorphic
and consequently not by itself pathogenic. Despite this,
our results suggest that the 15-bp sequence may have
some effect on VLCAD gene expression, rendering in-
dividuals susceptible to disease if a pathogenic mutation
is present in the other VLCAD allele. It is obvious, how-
ever, that further studies are needed to investigate this.
To investigate a possible genotype-phenotype rela-
tionship, we categorized the mutations into two classes
according to their severity: “null” mutations, which
would inevitably lead to no residual enzyme activity,
and missense mutations or single–amino acid deletions,
which might or might not lead to residual enzyme ac-
tivity (table 2).
Twenty-four of the mutations in our patients give rise
to a protein lacking vital parts of the enzyme because
of missplicing and/or direct or indirect introduction of
a PTC. These were all categorized as null mutations,
since the encoded protein would not be expected to have
any residual VLCAD enzyme activity. Furthermore, the
presence of a PTC (including those resulting from mis-
splicing) usually dramatically reduces the steady-state
amounts of mRNA (Maquat 1995). Consistent with this,
all of the PTC mutations that were investigated resulted
in severely decreased amounts of normal-sized VLCAD
mRNA. Several different mechanisms have been sug-
gested for PTC recognition and degradation of the
mRNA. All of them rely on recognition of the PTC by
some sort of “mRNA surveillance machinery,” followed
by degradation of the mutant mRNA either in the nu-
cleus or in the cytosol (Maquat 1995). In this context,
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our observation of VLCAD mRNA with intron 10 re-
tained is puzzling. Intron 10 contains an in-frame PTC,
and the intron 10–containing VLCAD mRNA should,
therefore, be recognized and degraded. Furthermore, the
amount of intron 10–containing VLCAD mRNA ap-
pears to be unaffected by mutations introducing PTCs
into the coding sequence upstream of intron 10. This
may indicate that turnover of intron 10–containing
VLCAD mRNAs is independent of the translational ma-
chinery, since this machinery would recognize the most
upstream PTC first. Further studies are clearly needed
to resolve this enigma, but there can be no doubt that
the identified PTC/splice mutations are null mutations.
The severity of the effects of the 31 identified missense
mutations and three single–amino acid deletions is more
difficult to evaluate. Our western blot analyses of patient
fibroblasts showed that all of the 43 mutations inves-
tigated lead to decreased steady-state amounts of
VLCAD protein (table 2). This finding, together with
the fact that as many as six of the identified mutations
are located in residues where mutation of the corre-
sponding residue in at least one other acyl-CoA dehy-
drogenase has been shown to cause disease (table 2),
may suggest that the molecular defect of the VLCAD
mutations is similar to that of mutations causing other
acyl-CoA dehydrogenase defects. In MCAD and SCAD
deficiencies, the majority of mutations cause compro-
mised folding or assembly of the acyl-CoA dehydroge-
nase protein, resulting in decreased amounts of func-
tional enzyme and varying degrees of residual enzyme
activity (Andresen et al. 1993, 1994, 1997; Bross et al.
1993, 1998; Gregersen et al. 1998). We observed con-
siderable levels of residual enzyme activity in the V243A
mutant protein and residual enzyme activity above back-
ground in the T220M mutant protein when we inves-
tigated them by overexpression in COS-7 cells. This
demonstrates that the two most frequent missense mu-
tations in VLCAD have a molecular-defect mechanism
that resembles that previously observed for the other
acyl-CoA dehydrogenases.
Although the various missense mutations and sin-
gle–amino acid deletions will result in different levels of
residual enzyme activity, we classified all of them (except
delK258 and R573W, which have both been demon-
strated by Souri et al. [1996] to have no residual enzyme
activity) as resulting in milder phenotypes than the null
mutations. Obviously, this is an oversimplification, but
nevertheless, we were able to observe a correlation be-
tween genotype and phenotype in the investigated fam-
ilies. In the severe childhood disease phenotype, the ma-
jority (71%) of identified alleles were of the null type,
whereas in the milder childhood and the adult disease
phenotypes, the majority of alleles (82% and 93%, re-
spectively) harbored mutations that might result in re-
sidual enzyme activity.
To make the correlation more precise, we excluded
patients who had one mutation of each type and com-
pared only the phenotypes of patients who had the same
type of mutation in both alleles (i.e., two null mutations
or two missense or single–amino acid deletion muta-
tions) (table 1). Fourteen of the patients with two null
mutations had the severe childhood phenotype, and only
a single patient had the mild childhood phenotype. Only
4 of the 18 patients with two missense or single–amino
acid deletion mutations had the severe childhood disease
phenotype. Interestingly, three of these patients were ho-
mozygous for the R429W mutation, suggesting that it
is a severe mutation with no residual enzyme activity,
like the mutations characterized by Souri et al. (1996,
1998a, 1998b). The remaining 14 patients with twomis-
sense or single–amino acid deletion mutations had the
mild childhood phenotype (9 patients) or adult onset of
the disease (5 patients).
The clear correlation of genotype with phenotype ob-
served in VLCAD deficiency is in sharp contrast to what
is observed in MCAD deficiency, in which we have so
far been unable to demonstrate any such correlation (An-
dresen et al. 1997). This difference may be attributable
to the fact that defective long-chain fatty acid oxidation
is less well tolerated than defective oxidation ofmedium-
chain fatty acids, because of the greater importance of
long-chain fatty acids as fuels, the greater toxicity of
long-chain acyl-CoAs (Corr et al. 1989; Fitzsimmons et
al. 1997; Paumen et al. 1998), or differences in the ef-
ficiency of alternative metabolic pathways for accumu-
lating long-chain and medium-chain fatty acyl-CoAs.
This notion is supported by the fact that patients with
CPT II deficiency, another defect of long-chain fatty acid
oxidation, show a correlation between genotype and
phenotype similar to that observed in VLCAD deficiency
(Taroni et al. 1993; Verderio et al. 1995; Bonnefont et
al. 1996).
An explanation for the observed genotype-phenotype
correlation could be as follows: In patients with two null
mutations, the complete absence of VLCAD activity will
affect many tissues, including the heart and liver, re-
sulting in cardiomyopathy, hepatomegaly, and recurrent
episodes of metabolic decompensation (severe pheno-
type). Patients with missense mutations or single–amino
acid deletion mutations may have sufficient residual
VLCAD activity, when receiving adequate nourishment,
to avoid liver and cardiac symptoms, and may not un-
dertake sufficient sustained exercise, in childhood, to
precipitate severe muscle symptoms. During infections
or fasting, however, the residual enzyme activity may no
longer be sufficient to sustain the increasing demand on
hepatic fatty acid oxidation, leading to hypoketotic hy-
poglycemia and encephalopathy. This notion is sup-
ported by the fact that, in all the patients with the mild
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childhood phenotype, the disease episodes were trig-
gered by such factors as fasting, vomiting, or fever.
As these patients get older, metabolic decompensation
becomes less of a problem, but they also start to un-
dertake more sustained exercise. The residual VLCAD
activity may not be sufficient to sustain the demands of
exercising muscle, particularly as muscle oxidizes fatty
acids in preference to glucose under many circumstances
(Kim et al. 1996). This leads to muscle symptoms, such
as exercise-induced rhabdomyolysis and myoglobinuria.
In six of our patients, who presented with the mild child-
hood phenotype and are now in their teens or late child-
hood, the symptoms have changed from episodes of hy-
poketotic hypoglycemia to muscle soreness, with
episodes of myoglobinuria in two patients. All of these
six patients have two missense or single–amino acid de-
letion mutations. The late onset of disease in the adult
patients could simply be the result of their avoiding met-
abolic stress to a sufficient extent, during childhood, to
prevent childhood precipitation of disease. Alternatively,
it is possible that they have mutations with higher re-
sidual enzyme activity than that observed in patients
with the mild childhood disease phenotype, resulting in
a difference in tolerance of metabolic stress between the
two groups of patients.
In addition to the environmental influences mentioned
above, other genetic factors may modify the phenotype
in VLCAD deficiency. Differences in the cellular han-
dling of mutant proteins, for example, could lead to
differences in the residual enzyme activity obtained from
identical mutations. Such processes are known to be im-
portant in SCAD and MCAD deficiencies (Andresen et
al. 1997; Bross et al. 1998; Gregersen et al. 1998). Given
that many VLCAD mutations also lead to decreased
steady-state protein levels, similar processes may operate
in this condition. Finally, because of LCAD’s overlap-
ping chain-length specificity, mutations in this enzyme
might modify the disease phenotype in VLCAD defi-
ciency. A study by Yamaguchi and coworkers (1993)
suggests that a 997ArC mutation in LCAD might have
such a role. Our results show, however, that themutation
is polymorphic in the normal population and that it is
unlikely to play a significant role in determining the
VLCAD phenotype (table 3). This conclusion is consis-
tent with the fact that LCAD is responsible for !10%
of the cellular enzyme activity toward palmitoyl-CoA
(Aoyama et al. 1995b; Vianey-Saban et al. 1998) and
seems to have a tissue-specific expression pattern differ-
ent from that of the other acyl-CoA dehydrogenases in
humans (Andresen et al. 1996a).
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